{"transactions":[{"id":713360,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Purchase Warrant","published_at":"2026-07-07T11:01:50.000Z","date":"2026-07-02","kind":"other","planned":false,"acquired":false,"shares":14801,"price":0.125,"value":1850.125,"ownership":{"direct":true},"balance_after":14802,"derivative":{"exercise_price":1.4,"exercise_date":"2026-07-02","expiration_date":"2027-12-31","underlying":"Common Stock","underlying_shares":14801},"source":{"system":"sec-edgar","filing":"0001213900-26-075738","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026075738/ownership.xml","form_type":"4"}},{"id":713359,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T11:01:50.000Z","date":"2026-07-02","kind":"exercise","planned":false,"acquired":true,"shares":14801,"price":1.4,"value":20721.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 14,801 shares of Common Stock acquired upon exercise of common stock purchase warrants held by the Reporting Person. The Reporting Person and other holders of common stock purchase warrants previously issued by the Issuer in its April 2024 offerings on April 24, 2024 and April 29, 2024, as such warrants were amended on December 22, 2025 (the \"April 2024 Warrants\"), entered into a warrant inducement offer letter agreement with the Issuer (the \"Inducement Letter\"). Pursuant to the Inducement Letter, the Reporting Person agreed to exercise, for cash, 14,801 April 2024 Warrants, representing 50% of the April 2024 Warrants held by it, and agreed to purchase 14,801 shares of common stock at a reduced exercise price of $1.40 in exchange for the Issuer's agreement to extend the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were not exercised, from June 30, 2026, to December 31, 2027."}],"balance_after":86404,"source":{"system":"sec-edgar","filing":"0001213900-26-075738","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026075738/ownership.xml","form_type":"4"}},{"id":983164,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-12-02T21:40:56.000Z","date":"2025-12-01","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the Issuer's Second Amended and Restated 2021 Stock Incentive Plan. The option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the option is 100% vested, which shall occur on the three-year anniversary of the date of grant."}],"balance_after":150000,"derivative":{"exercise_price":1.48,"expiration_date":"2035-11-23","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001213900-25-117303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025117303/ownership.xml","form_type":"4"}},{"id":995050,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":12500,"derivative":{"exercise_price":1.5,"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995049,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":9.92,"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995048,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":32500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":32500,"derivative":{"exercise_price":1.5,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995047,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":5.05,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995046,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":35000,"derivative":{"exercise_price":1.5,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995045,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":9.74,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995044,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":35000,"derivative":{"exercise_price":1.5,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995043,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.92,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995042,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":19025,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":19025,"derivative":{"exercise_price":1.5,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":19025},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995041,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19025,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":17.49,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":19025},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995040,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":15975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":15975,"derivative":{"exercise_price":1.5,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":15975},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995039,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":24.82,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":15975},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995038,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":108000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":108000,"derivative":{"exercise_price":1.5,"expiration_date":"2029-11-24","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995037,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":108000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":3.91,"expiration_date":"2029-11-24","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995036,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"grant","planned":false,"acquired":true,"shares":108000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":108000,"derivative":{"exercise_price":1.5,"expiration_date":"2028-04-01","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":995035,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T22:27:48.000Z","date":"2025-11-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":108000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of November 18, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2017 Stock Incentive Plan (the \"2017 Plan\"), 2019 Stock Incentive Plan (the \"2019 Plan\"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the \"2021 Plan\") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.8,"expiration_date":"2028-04-01","underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-25-112232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025112232/ownership.xml","form_type":"4"}},{"id":1338591,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-12-09T21:00:27.000Z","date":"2024-12-05","kind":"grant","planned":false,"acquired":true,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the 2021 Stock Incentive Plan. The option will become 100% vested and exercisable on December 5, 2026, the two-year anniversary of the grant date."}],"balance_after":32500,"derivative":{"exercise_price":5.05,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001213900-24-106915","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024106915/ownership.xml","form_type":"4"}},{"id":1468576,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-26T12:00:03.000Z","date":"2024-06-25","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":7.27,"value":36350.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person's shares are held by Fossick Capital LP (\"Fossick\"), a limited partnership. The Reporting Person holds all voting and dispositive control over the Issuer's shares of common stock held by Fossick."}],"balance_after":71603,"source":{"system":"sec-edgar","filing":"0001213900-24-055920","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024055920/ownership.xml","form_type":"4"}},{"id":1513758,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-05-16T20:08:07.000Z","date":"2024-05-14","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the 2021 Stock Incentive Plan. The Option will become vested and exercisable 1/12th every month until the Option is 100% vested which shall occur on the one-year anniversary of the grant date."}],"balance_after":12500,"derivative":{"exercise_price":9.92,"expiration_date":"2034-05-13","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001213900-24-044306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024044306/ownership.xml","form_type":"4"}},{"id":1535987,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrants (right to buy)","published_at":"2024-04-24T18:07:17.000Z","date":"2024-04-19","kind":"purchase","planned":false,"acquired":true,"shares":29603,"price":0.125,"value":3700.375,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $249,997.34 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the \"Termination Date\") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant."}],"balance_after":29603,"derivative":{"exercise_price":9.152,"exercise_date":"2024-04-24","underlying":"Common Stock","underlying_shares":29603},"source":{"system":"sec-edgar","filing":"0001213900-24-035720","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024035720/ownership.xml","form_type":"4/A","original_submission_date":"2024-04-23"}},{"id":1535986,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-24T18:07:17.000Z","date":"2024-04-19","kind":"purchase","planned":false,"acquired":true,"shares":29603,"price":8.32,"value":246296.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $249,997.34 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the \"Termination Date\") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant."}],"balance_after":66603,"source":{"system":"sec-edgar","filing":"0001213900-24-035720","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024035720/ownership.xml","form_type":"4/A","original_submission_date":"2024-04-23"}},{"id":1536680,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrants (right to buy)","published_at":"2024-04-23T21:53:47.000Z","date":"2024-04-19","kind":"grant","planned":false,"acquired":true,"shares":29603,"price":0.125,"value":3700.375,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $249,997.34 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the \"Termination Date\") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant."}],"balance_after":29603,"derivative":{"exercise_price":9.152,"exercise_date":"2024-04-24","underlying":"Common Stock","underlying_shares":29603},"source":{"system":"sec-edgar","filing":"0001213900-24-035471","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024035471/ownership.xml","form_type":"4"}},{"id":1536679,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-23T21:53:47.000Z","date":"2024-04-19","kind":"grant","planned":false,"acquired":true,"shares":29603,"price":8.32,"value":246296.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $249,997.34 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the \"Termination Date\") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant."}],"balance_after":66603,"source":{"system":"sec-edgar","filing":"0001213900-24-035471","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024035471/ownership.xml","form_type":"4"}},{"id":1743355,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-13T16:31:53.000Z","date":"2023-11-10","kind":"purchase","planned":false,"acquired":true,"shares":7000,"price":6.95,"value":48650.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person's shares are held by Fossick Capital LP (\"Fossick\"), a limited partnership. The Reporting Person holds all voting and dispositive control over the Issuer's shares of common stock held by Fossick."}],"balance_after":37000,"source":{"system":"sec-edgar","filing":"0001213900-23-085758","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390023085758/ownership.xml","form_type":"4"}},{"id":2002766,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2023-02-21T21:08:40.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date."}],"balance_after":35000,"derivative":{"exercise_price":9.74,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-23-013284","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390023013284/ownership.xml","form_type":"4"}},{"id":2319681,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2022-03-23T20:29:41.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date."}],"balance_after":35000,"derivative":{"exercise_price":7.92,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001213900-22-014500","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390022014500/ownership.xml","form_type":"4"}},{"id":2506175,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-17T23:10:36.000Z","date":"2021-11-17","kind":"purchase","acquired":true,"shares":2500,"price":13.55,"value":33875.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person's shares are held by Fossick Capital LP (\"Fossick\"), a limited partnership. The Reporting Person holds all voting and dispositive control over the Issuer's shares of common stock held by Fossick."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001213900-21-060386","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390021060386/ownership.xml","form_type":"4"}},{"id":2655473,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-06-24T21:54:06.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":19025,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each Option represents a right to receive one share of common stock of INmune Bio, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options granted pursuant to the Company's 2021 Stock Incentive Plan. These Options vest on a pro rata quarterly basis over three years such that all options to purchase the 19,025 shares will have vested on the third anniversary of the grant date."}],"balance_after":19025,"derivative":{"exercise_price":17.49,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":19025},"source":{"system":"sec-edgar","filing":"0001213900-21-034012","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390021034012/ownership.xml","form_type":"4"}},{"id":2900186,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-01-21T21:34:49.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":15975,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each Option represents a right to receive one share of common stock of INmune Bio, Inc."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options granted pursuant to 2019 Stock Incentive Plan. Options shall vest on a pro rata quarterly basis over three years such that all options to purchase the 15,975 shares will have vested on the third anniversary of the grant date."}],"balance_after":15975,"derivative":{"exercise_price":24.82,"expiration_date":"2031-01-18","underlying":"Common Stock","underlying_shares":15975},"source":{"system":"sec-edgar","filing":"0001213900-21-003484","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390021003484/ownership.xml","form_type":"4"}},{"id":3357025,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option","published_at":"2019-11-27T21:36:34.000Z","date":"2019-11-25","kind":"grant","acquired":true,"shares":108000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each Option represents a right to receive one share of common stock of INmune Bio, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant."}],"balance_after":216000,"derivative":{"exercise_price":3.91,"underlying":"Common Stock","underlying_shares":108000},"source":{"system":"sec-edgar","filing":"0001213900-19-024954","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390019024954/ownership.xml","form_type":"4"}},{"id":3430761,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-22T20:30:33.000Z","date":"2019-08-21","kind":"purchase","acquired":true,"shares":2500,"price":6,"value":15000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person purchased 2,500 shares of the Issuer's common stock in an open market transaction on August 20, 2019 and 2,5000 shares of the Issuer's common stock in an open market transaction on August 21, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person's shares are held by Fossick Capital LP (\"Fossick\"), a limited partnership. The Reporting Person holds all voting and dispositive control over the Issuer's shares of common stock held by Fossick."}],"balance_after":27500,"source":{"system":"sec-edgar","filing":"0001213900-19-016514","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390019016514/ownership.xml","form_type":"4"}},{"id":3430760,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":31621,"kind":"person","name":"Juda Scott","position":1,"cik":"0001767084","reported_name":"Juda Scott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-22T20:30:33.000Z","date":"2019-08-20","kind":"purchase","acquired":true,"shares":2500,"price":6,"value":15000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person purchased 2,500 shares of the Issuer's common stock in an open market transaction on August 20, 2019 and 2,5000 shares of the Issuer's common stock in an open market transaction on August 21, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person's shares are held by Fossick Capital LP (\"Fossick\"), a limited partnership. The Reporting Person holds all voting and dispositive control over the Issuer's shares of common stock held by Fossick."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001213900-19-016514","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390019016514/ownership.xml","form_type":"4"}}]}